Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15613223,T(max),"The median T(max) for rizatriptan between and during attacks was 1 hour, indicating rapid absorption even during a migraine attack.",Pharmacokinetics of rizatriptan tablets during and between migraine attacks. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15613223/),h,1,18448,DB00953,Rizatriptan
,25488888,Фmax1B,"Our calculations showed that Фmax1B and Фmax1D were relatively high at 32.0-89.4% and 68.4-96.2%, respectively, suggesting that it is likely that a high occupancy is necessary to attain the clinical effect.",Theory-based analysis of clinical efficacy of triptans using receptor occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488888/),%,32.0-89.4,43895,DB00953,Rizatriptan
,25488888,Фmax,"Our calculations showed that Фmax1B and Фmax1D were relatively high at 32.0-89.4% and 68.4-96.2%, respectively, suggesting that it is likely that a high occupancy is necessary to attain the clinical effect.",Theory-based analysis of clinical efficacy of triptans using receptor occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488888/),%,32.0-89.4,43896,DB00953,Rizatriptan
,10233200,AUC,"The arithmetic mean AUC values following single oral doses of 2.5, 5, 10, and 15-mg rizatriptan were 16, 33, 72, and 127 ng ml-1 h, respectively, in males; and 19, 42, 97, and 161 ng ml-1 h, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[h·ng] / [ml],16,59281,DB00953,Rizatriptan
,10233200,AUC,"The arithmetic mean AUC values following single oral doses of 2.5, 5, 10, and 15-mg rizatriptan were 16, 33, 72, and 127 ng ml-1 h, respectively, in males; and 19, 42, 97, and 161 ng ml-1 h, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[h·ng] / [ml],33,59282,DB00953,Rizatriptan
,10233200,AUC,"The arithmetic mean AUC values following single oral doses of 2.5, 5, 10, and 15-mg rizatriptan were 16, 33, 72, and 127 ng ml-1 h, respectively, in males; and 19, 42, 97, and 161 ng ml-1 h, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[h·ng] / [ml],72,59283,DB00953,Rizatriptan
,10233200,AUC,"The arithmetic mean AUC values following single oral doses of 2.5, 5, 10, and 15-mg rizatriptan were 16, 33, 72, and 127 ng ml-1 h, respectively, in males; and 19, 42, 97, and 161 ng ml-1 h, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[h·ng] / [ml],127,59284,DB00953,Rizatriptan
,10233200,AUC,"The arithmetic mean AUC values following single oral doses of 2.5, 5, 10, and 15-mg rizatriptan were 16, 33, 72, and 127 ng ml-1 h, respectively, in males; and 19, 42, 97, and 161 ng ml-1 h, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[h·ng] / [ml],19,59285,DB00953,Rizatriptan
,10233200,AUC,"The arithmetic mean AUC values following single oral doses of 2.5, 5, 10, and 15-mg rizatriptan were 16, 33, 72, and 127 ng ml-1 h, respectively, in males; and 19, 42, 97, and 161 ng ml-1 h, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[h·ng] / [ml],42,59286,DB00953,Rizatriptan
,10233200,AUC,"The arithmetic mean AUC values following single oral doses of 2.5, 5, 10, and 15-mg rizatriptan were 16, 33, 72, and 127 ng ml-1 h, respectively, in males; and 19, 42, 97, and 161 ng ml-1 h, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[h·ng] / [ml],97,59287,DB00953,Rizatriptan
,10233200,AUC,"The arithmetic mean AUC values following single oral doses of 2.5, 5, 10, and 15-mg rizatriptan were 16, 33, 72, and 127 ng ml-1 h, respectively, in males; and 19, 42, 97, and 161 ng ml-1 h, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[h·ng] / [ml],161,59288,DB00953,Rizatriptan
,10233200,overall bioavailability (F ),The overall bioavailability (F ) of rizatriptan was approximately 40% in males.,Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),%,40,59289,DB00953,Rizatriptan
,10233200,apparent plasma clearance (CL),"Following the 4 mg reference i.v. dose, the apparent plasma clearance (CL) and renal clearance (CLr ) were 1042 and 225 ml min-1, respectively, in males; and 821 and 174 ml min-1, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[ml] / [min],1042,59290,DB00953,Rizatriptan
,10233200,apparent plasma clearance (CL),"Following the 4 mg reference i.v. dose, the apparent plasma clearance (CL) and renal clearance (CLr ) were 1042 and 225 ml min-1, respectively, in males; and 821 and 174 ml min-1, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[ml] / [min],821,59291,DB00953,Rizatriptan
,10233200,renal clearance (CLr ),"Following the 4 mg reference i.v. dose, the apparent plasma clearance (CL) and renal clearance (CLr ) were 1042 and 225 ml min-1, respectively, in males; and 821 and 174 ml min-1, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[ml] / [min],225,59292,DB00953,Rizatriptan
,10233200,renal clearance (CLr ),"Following the 4 mg reference i.v. dose, the apparent plasma clearance (CL) and renal clearance (CLr ) were 1042 and 225 ml min-1, respectively, in males; and 821 and 174 ml min-1, respectively, in females.",Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233200/),[ml] / [min],174,59293,DB00953,Rizatriptan
,26310617,Tmax,"The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively.",Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310617/),h,1.00,74067,DB00953,Rizatriptan
,26310617,Cmax,"The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively.",Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310617/),[ng] / [ml],64.13,74068,DB00953,Rizatriptan
,26310617,Cmax,"The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively.",Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310617/),[ng] / [ml],38.00,74069,DB00953,Rizatriptan
,26310617,Cmax,"The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively.",Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310617/),[ng] / [h·ml],210.38,74070,DB00953,Rizatriptan
,26310617,AUC,"The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively.",Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310617/),[ng] / [ml],64.13,74071,DB00953,Rizatriptan
,26310617,AUC,"The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively.",Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310617/),[ng] / [ml],38.00,74072,DB00953,Rizatriptan
,26310617,AUC,"The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively.",Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310617/),[ng] / [h·ml],210.38,74073,DB00953,Rizatriptan
,26310617,t1/2,"The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively.",Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310617/),h,3.09,74074,DB00953,Rizatriptan
,26310617,t1/2,"The Tmax, Cmax, AUC and t1/2 for oral strip were found to be 1.00 h, 64.13±19.46 ng/mL, 352.00±71.57 ng/mL/h and 3.09±1.03 h respectively, whereas, tablet showed 1.5 h, 38.00±13.43 ng/mL, 210.38± 40.37ng/mL/h and 1.66±0.31 h respectively.",Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26310617/),h,1.66,74075,DB00953,Rizatriptan
,10611145,total recovery of radioactivity,"In a two-period, single i.v. (3 mg, 30-min infusion), and single oral (10 mg) dose study with [(14)C]rizatriptan in six healthy human males, total recovery of radioactivity was approximately 94%, with unchanged rizatriptan and its metabolites being excreted mainly in the urine (89% i.v. dose, 82% p.o. dose).","Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611145/),%,94,80343,DB00953,Rizatriptan
,10611145,total recovery of radioactivity,"In a two-period, single i.v. (3 mg, 30-min infusion), and single oral (10 mg) dose study with [(14)C]rizatriptan in six healthy human males, total recovery of radioactivity was approximately 94%, with unchanged rizatriptan and its metabolites being excreted mainly in the urine (89% i.v. dose, 82% p.o. dose).","Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611145/),%,89,80344,DB00953,Rizatriptan
,10611145,total recovery of radioactivity,"In a two-period, single i.v. (3 mg, 30-min infusion), and single oral (10 mg) dose study with [(14)C]rizatriptan in six healthy human males, total recovery of radioactivity was approximately 94%, with unchanged rizatriptan and its metabolites being excreted mainly in the urine (89% i.v. dose, 82% p.o. dose).","Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611145/),%,82,80345,DB00953,Rizatriptan
,10611145,Plasma clearance (CL),"Plasma clearance (CL) and renal clearance (CL(r)) were 1325 and 349 ml/min, respectively, after i.v. administration.","Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611145/),[ml] / [min],1325,80346,DB00953,Rizatriptan
,10611145,renal clearance (CL(r)),"Plasma clearance (CL) and renal clearance (CL(r)) were 1325 and 349 ml/min, respectively, after i.v. administration.","Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611145/),[ml] / [min],349,80347,DB00953,Rizatriptan
,10611145,CL(r),A similar CL(r) value was obtained after oral administration (396 ml/min).,"Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611145/),[ml] / [min],396,80348,DB00953,Rizatriptan
,10611145,absorption,"The absorption of rizatriptan was approximately 90%, but it experienced a moderate first-pass effect, resulting in a bioavailability estimate of 47%.","Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611145/),%,90,80349,DB00953,Rizatriptan
,10611145,bioavailability,"The absorption of rizatriptan was approximately 90%, but it experienced a moderate first-pass effect, resulting in a bioavailability estimate of 47%.","Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611145/),%,47,80350,DB00953,Rizatriptan
,11680669,AUC(0-infinity),"In elderly subjects, the geometric mean values for AUC(0-infinity) and Cmax were 77.7 ng/h/ml and 21.9 ng/ml; the average values for tmax, half-life (t 1/2), renal clearance (Clr), and percent urinary excretion of dose (Ue) were 1.2 h, 1.8 h, 197 ml/min and 9.3%, respectively.",Pharmacokinetics of rizatriptan in healthy elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680669/),[ng] / [h·ml],77.7,82152,DB00953,Rizatriptan
,11680669,Cmax,"In elderly subjects, the geometric mean values for AUC(0-infinity) and Cmax were 77.7 ng/h/ml and 21.9 ng/ml; the average values for tmax, half-life (t 1/2), renal clearance (Clr), and percent urinary excretion of dose (Ue) were 1.2 h, 1.8 h, 197 ml/min and 9.3%, respectively.",Pharmacokinetics of rizatriptan in healthy elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680669/),[ng] / [ml],21.9,82153,DB00953,Rizatriptan
,11680669,tmax,"In elderly subjects, the geometric mean values for AUC(0-infinity) and Cmax were 77.7 ng/h/ml and 21.9 ng/ml; the average values for tmax, half-life (t 1/2), renal clearance (Clr), and percent urinary excretion of dose (Ue) were 1.2 h, 1.8 h, 197 ml/min and 9.3%, respectively.",Pharmacokinetics of rizatriptan in healthy elderly subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680669/),h,1.2,82154,DB00953,Rizatriptan
,11680669,half-life (t 1/2),"In elderly subjects, the geometric mean values for AUC(0-infinity) and Cmax were 77.7 ng/h/ml and 21.9 ng/ml; the average values for tmax, half-life (t 1/2), renal clearance (Clr), and percent urinary excretion of dose (Ue) were 1.2 h, 1.8 h, 197 ml/min and 9.3%, respectively.",Pharmacokinetics of rizatriptan in healthy elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680669/),h,1.8,82155,DB00953,Rizatriptan
,11680669,half-life (t 1/2),"In elderly subjects, the geometric mean values for AUC(0-infinity) and Cmax were 77.7 ng/h/ml and 21.9 ng/ml; the average values for tmax, half-life (t 1/2), renal clearance (Clr), and percent urinary excretion of dose (Ue) were 1.2 h, 1.8 h, 197 ml/min and 9.3%, respectively.",Pharmacokinetics of rizatriptan in healthy elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680669/),[ml] / [min],197,82156,DB00953,Rizatriptan
,11680669,renal clearance (Clr),"In elderly subjects, the geometric mean values for AUC(0-infinity) and Cmax were 77.7 ng/h/ml and 21.9 ng/ml; the average values for tmax, half-life (t 1/2), renal clearance (Clr), and percent urinary excretion of dose (Ue) were 1.2 h, 1.8 h, 197 ml/min and 9.3%, respectively.",Pharmacokinetics of rizatriptan in healthy elderly subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680669/),h,1.8,82157,DB00953,Rizatriptan
,11680669,renal clearance (Clr),"In elderly subjects, the geometric mean values for AUC(0-infinity) and Cmax were 77.7 ng/h/ml and 21.9 ng/ml; the average values for tmax, half-life (t 1/2), renal clearance (Clr), and percent urinary excretion of dose (Ue) were 1.2 h, 1.8 h, 197 ml/min and 9.3%, respectively.",Pharmacokinetics of rizatriptan in healthy elderly subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680669/),[ml] / [min],197,82158,DB00953,Rizatriptan
,11680669,percent urinary excretion of dose (Ue),"In elderly subjects, the geometric mean values for AUC(0-infinity) and Cmax were 77.7 ng/h/ml and 21.9 ng/ml; the average values for tmax, half-life (t 1/2), renal clearance (Clr), and percent urinary excretion of dose (Ue) were 1.2 h, 1.8 h, 197 ml/min and 9.3%, respectively.",Pharmacokinetics of rizatriptan in healthy elderly subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680669/),%,9.3,82159,DB00953,Rizatriptan
,26242873,occup,"For Ф1D, it was indicated that all triptans obtained an occupancy of 80% or higher at maximum.",Theoretical analysis of headache recurrence in patients administered triptans for migraine based on receptor occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242873/),%,80,83156,DB00953,Rizatriptan
,28618340,flow rate,A simple isocratic separation mode was used with a mobile phase consisted of acetonitrile and 10mM phosphate buffer adjusted to pH 3.0 (20:80; v/v) at flow rate 1.0mLmin-1.,Fast and efficient zirconia-based reversed phase chromatography for selective determination of triptans in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618340/),1/[mlmin],1.0,86345,DB00953,Rizatriptan
,28618340,detection limits,The linearity range obtained for the developed HPLC method was 15-2000ngmL-1 with detection limits of 4.8- 6.2ngmL-1 for all the studied triptans.,Fast and efficient zirconia-based reversed phase chromatography for selective determination of triptans in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28618340/),1/[ngml],4.8- 6.2,86346,DB00953,Rizatriptan
,9056052,tmax,"MK-462 was rapidly absorbed with a median tmax of 1.3 h (range 1-3 h) vs a tmax for sumatriptan of 2.5 h (range 1-4 h, P < 0.001).",Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056052/),h,1.3,115982,DB00953,Rizatriptan
,9056052,tmax,"MK-462 was rapidly absorbed with a median tmax of 1.3 h (range 1-3 h) vs a tmax for sumatriptan of 2.5 h (range 1-4 h, P < 0.001).",Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056052/),h,2.5,115983,DB00953,Rizatriptan
,11327198,bioavailability,"For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan).",Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327198/),%,14,123788,DB00953,Rizatriptan
,11327198,bioavailability,"For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan).",Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327198/),%,74,123789,DB00953,Rizatriptan
,11327198,elimination half-life,"For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan).",Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327198/),h,2,123790,DB00953,Rizatriptan
,11327198,elimination half-life,"For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan).",Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327198/),h,25,123791,DB00953,Rizatriptan
,31593810,Tmax,Absorption from oral tablet is slow with Tmax of approximately 1-1.5 h.,Intranasal spray formulation containing rizatriptan benzoate for the treatment of migraine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31593810/),h,1-1.5,127007,DB00953,Rizatriptan
more,31593810,solubility,"Binary and ternary co-solvents using ethanol, water, propylene glycol and polyethylene glycol resulted rizatriptan equivalent base solubility more than 60 mg/mL.",Intranasal spray formulation containing rizatriptan benzoate for the treatment of migraine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31593810/),[mg] / [ml],60,127008,DB00953,Rizatriptan
,31593810,Cmax,"Nasal spray formulation containing 20% w/w ethanol exhibited highest exposure, where Cmax (312 ng/mL) reached in 5 min and maintained higher concentration than oral dose for more than 30 min.",Intranasal spray formulation containing rizatriptan benzoate for the treatment of migraine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31593810/),[ng] / [ml],312,127009,DB00953,Rizatriptan
,16899417,total run time,The method had a chromatographic total run time of 2 min.,Development and validation of a selective and robust LC-MS/MS method for high-throughput quantifying rizatriptan in small plasma samples: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16899417/),min,2,142084,DB00953,Rizatriptan
above,16899417,extraction recovery,The mean extraction recovery from spiked plasma samples was above 98%.,Development and validation of a selective and robust LC-MS/MS method for high-throughput quantifying rizatriptan in small plasma samples: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16899417/),%,98,142085,DB00953,Rizatriptan
,25092964,time to maximum concentration,"Although the time to maximum concentration was similar for both drugs (2.7 versus 2.3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29.3 versus 3.2 hours, P<0.0001).",Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092964/),h,2.7,142145,DB00953,Rizatriptan
,25092964,time to maximum concentration,"Although the time to maximum concentration was similar for both drugs (2.7 versus 2.3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29.3 versus 3.2 hours, P<0.0001).",Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092964/),h,2.3,142146,DB00953,Rizatriptan
,25092964,terminal half-life,"Although the time to maximum concentration was similar for both drugs (2.7 versus 2.3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29.3 versus 3.2 hours, P<0.0001).",Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092964/),h,29.3,142147,DB00953,Rizatriptan
,25092964,terminal half-life,"Although the time to maximum concentration was similar for both drugs (2.7 versus 2.3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29.3 versus 3.2 hours, P<0.0001).",Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092964/),h,3.2,142148,DB00953,Rizatriptan
,17267150,absolute bioavailability,"Following the intratracheal administration of the drug (4.0mg/kg) to the rats, the absolute bioavailability was found to be 91.2%, significantly higher than those from intranasal or peroral routes, and T(max) in plasma and brain was attained within 2 min, significantly shorter than the T(max) of intranasal ( approximately 10 min in both plasma and brain), subcutaneous (16.7 min in plasma and 22.5 min in brain) and peroral (30.0 min in plasma and 45.0 min in brain) administration.",Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267150/),%,91.2,149866,DB00953,Rizatriptan
,17267150,T(max),"Following the intratracheal administration of the drug (4.0mg/kg) to the rats, the absolute bioavailability was found to be 91.2%, significantly higher than those from intranasal or peroral routes, and T(max) in plasma and brain was attained within 2 min, significantly shorter than the T(max) of intranasal ( approximately 10 min in both plasma and brain), subcutaneous (16.7 min in plasma and 22.5 min in brain) and peroral (30.0 min in plasma and 45.0 min in brain) administration.",Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267150/),min,10,149867,DB00953,Rizatriptan
,17267150,T(max),"Following the intratracheal administration of the drug (4.0mg/kg) to the rats, the absolute bioavailability was found to be 91.2%, significantly higher than those from intranasal or peroral routes, and T(max) in plasma and brain was attained within 2 min, significantly shorter than the T(max) of intranasal ( approximately 10 min in both plasma and brain), subcutaneous (16.7 min in plasma and 22.5 min in brain) and peroral (30.0 min in plasma and 45.0 min in brain) administration.",Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267150/),min,16.7,149868,DB00953,Rizatriptan
,17267150,T(max),"Following the intratracheal administration of the drug (4.0mg/kg) to the rats, the absolute bioavailability was found to be 91.2%, significantly higher than those from intranasal or peroral routes, and T(max) in plasma and brain was attained within 2 min, significantly shorter than the T(max) of intranasal ( approximately 10 min in both plasma and brain), subcutaneous (16.7 min in plasma and 22.5 min in brain) and peroral (30.0 min in plasma and 45.0 min in brain) administration.",Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267150/),min,22.5,149869,DB00953,Rizatriptan
,17267150,T(max),"Following the intratracheal administration of the drug (4.0mg/kg) to the rats, the absolute bioavailability was found to be 91.2%, significantly higher than those from intranasal or peroral routes, and T(max) in plasma and brain was attained within 2 min, significantly shorter than the T(max) of intranasal ( approximately 10 min in both plasma and brain), subcutaneous (16.7 min in plasma and 22.5 min in brain) and peroral (30.0 min in plasma and 45.0 min in brain) administration.",Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267150/),min,30.0,149870,DB00953,Rizatriptan
,17267150,T(max),"Following the intratracheal administration of the drug (4.0mg/kg) to the rats, the absolute bioavailability was found to be 91.2%, significantly higher than those from intranasal or peroral routes, and T(max) in plasma and brain was attained within 2 min, significantly shorter than the T(max) of intranasal ( approximately 10 min in both plasma and brain), subcutaneous (16.7 min in plasma and 22.5 min in brain) and peroral (30.0 min in plasma and 45.0 min in brain) administration.",Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267150/),min,45.0,149871,DB00953,Rizatriptan
,17267150,AUC(brain,"Although AUC(brain)/AUC(plasma) ratios after intranasal delivery (43.4%) differed significantly from the ratios shown after intratracheal instillation (23.2%), the AUC(brain 0-120 min) via the latter routes was slightly but not significantly higher than that from the former routes.",Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267150/),%,43.4,149872,DB00953,Rizatriptan
,17267150,AUC(brain,"Although AUC(brain)/AUC(plasma) ratios after intranasal delivery (43.4%) differed significantly from the ratios shown after intratracheal instillation (23.2%), the AUC(brain 0-120 min) via the latter routes was slightly but not significantly higher than that from the former routes.",Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267150/),%,23.2,149873,DB00953,Rizatriptan
,15056946,T(max),"Pharmacokinetic study demonstrated the approximate T(max) of 1.0 or 1.1 h in tablets and 1.3 h in RPD tablets, resulting in early onset for headache relief and also pain free.","[Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15056946/),h,1.0,153560,DB00953,Rizatriptan
,15056946,T(max),"Pharmacokinetic study demonstrated the approximate T(max) of 1.0 or 1.1 h in tablets and 1.3 h in RPD tablets, resulting in early onset for headache relief and also pain free.","[Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15056946/),h,1.1,153561,DB00953,Rizatriptan
,15056946,T(max),"Pharmacokinetic study demonstrated the approximate T(max) of 1.0 or 1.1 h in tablets and 1.3 h in RPD tablets, resulting in early onset for headache relief and also pain free.","[Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15056946/),h,1.3,153562,DB00953,Rizatriptan
,15056946,Bioavailability,Bioavailability was estimated to be about 45%.,"[Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15056946/),%,45,153563,DB00953,Rizatriptan
,27757013,terminal elimination half-life in blood,Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours).,Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27757013/),h,26,182748,DB00953,Rizatriptan
,10637423,limits of detection (LOD),The limits of detection (LOD) for the method were 250 pg/mL for sumatriptan and 100 pg/mL for the remaining analytes based on a signal-to-noise ratio of 3.,"Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637423/),[pg] / [ml],250,185085,DB00953,Rizatriptan
,10637423,limits of detection (LOD),The limits of detection (LOD) for the method were 250 pg/mL for sumatriptan and 100 pg/mL for the remaining analytes based on a signal-to-noise ratio of 3.,"Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637423/),[pg] / [ml],100,185086,DB00953,Rizatriptan
,10637423,signal-to-noise ratio,The limits of detection (LOD) for the method were 250 pg/mL for sumatriptan and 100 pg/mL for the remaining analytes based on a signal-to-noise ratio of 3.,"Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10637423/),,3,185087,DB00953,Rizatriptan
,22289113,area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],56.68,193499,DB00953,Rizatriptan
,22289113,area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],78.49,193500,DB00953,Rizatriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],56.68,193501,DB00953,Rizatriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],22.39,193502,DB00953,Rizatriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],78.49,193503,DB00953,Rizatriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],22.27,193504,DB00953,Rizatriptan
,16432269,AUC(0-2h),ODTc had a statistically significantly greater geometric mean AUC(0-2h) compared with ODTs (33.84 h x ng/mL vs 18.83 h x ng/mL; P < .001).,"Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432269/),[h·ng] / [ml],33.84,193977,DB00953,Rizatriptan
,16432269,AUC(0-2h),ODTc had a statistically significantly greater geometric mean AUC(0-2h) compared with ODTs (33.84 h x ng/mL vs 18.83 h x ng/mL; P < .001).,"Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432269/),[h·ng] / [ml],18.83,193978,DB00953,Rizatriptan
,16432269,AUC(0-1h),"ODTc had a slightly, but not statistically significantly, greater geometric mean AUC(0-1h) compared with rizatriptan tablet (17.07 h x ng/mL vs 13.32 h x ng/mL).","Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432269/),[h·ng] / [ml],17.07,193979,DB00953,Rizatriptan
,16432269,AUC(0-1h),"ODTc had a slightly, but not statistically significantly, greater geometric mean AUC(0-1h) compared with rizatriptan tablet (17.07 h x ng/mL vs 13.32 h x ng/mL).","Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432269/),[h·ng] / [ml],13.32,193980,DB00953,Rizatriptan
,16432269,t(max),The median t(max) was 0.67 hours for ODTc and tablet and 1.33 hours for ODTs.,"Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432269/),h,0.67,193981,DB00953,Rizatriptan
,16432269,t(max),The median t(max) was 0.67 hours for ODTc and tablet and 1.33 hours for ODTs.,"Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432269/),h,1.33,193982,DB00953,Rizatriptan
,32716291,AUC0-tlast,"The geometric means of the parameters related with the extent of total exposure, i.e., AUC0-tlast and AUC0-∞, were 60.285 ng × h/mL and 60.865 ng × h/mL for test and 62.729 ng × h/mL and 63.312 ng × h/mL for reference, respectively.",A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716291/),[h·ng] / [ml],60.285,195426,DB00953,Rizatriptan
,32716291,AUC0-tlast,"The geometric means of the parameters related with the extent of total exposure, i.e., AUC0-tlast and AUC0-∞, were 60.285 ng × h/mL and 60.865 ng × h/mL for test and 62.729 ng × h/mL and 63.312 ng × h/mL for reference, respectively.",A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716291/),[h·ng] / [ml],62.729,195427,DB00953,Rizatriptan
,32716291,AUC0-∞,"The geometric means of the parameters related with the extent of total exposure, i.e., AUC0-tlast and AUC0-∞, were 60.285 ng × h/mL and 60.865 ng × h/mL for test and 62.729 ng × h/mL and 63.312 ng × h/mL for reference, respectively.",A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716291/),[h·ng] / [ml],60.865,195428,DB00953,Rizatriptan
,32716291,AUC0-∞,"The geometric means of the parameters related with the extent of total exposure, i.e., AUC0-tlast and AUC0-∞, were 60.285 ng × h/mL and 60.865 ng × h/mL for test and 62.729 ng × h/mL and 63.312 ng × h/mL for reference, respectively.",A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716291/),[h·ng] / [ml],63.312,195429,DB00953,Rizatriptan
,32716291,peak exposure,"The geometric means of the peak exposure, i.e., Cmax, were 21.262 ng/mL for test and 21.447 ng/mL for reference.",A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716291/),[ng] / [ml],21.262,195430,DB00953,Rizatriptan
,32716291,peak exposure,"The geometric means of the peak exposure, i.e., Cmax, were 21.262 ng/mL for test and 21.447 ng/mL for reference.",A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32716291/),[ng] / [ml],21.447,195431,DB00953,Rizatriptan
,15702515,relative bioavailability,The relative bioavailability of nasal formulation to oral formulation was 96%+/-16%.,Intranasal absorption of rizatriptan--in vivo pharmacokinetics and bioavailability study in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15702515/),%,96,228784,DB00953,Rizatriptan
,8991488,plasma clearance (CL),"The values of the plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRT) of MK-462 averaged 1376 mL min-1, 140 L, 1.8 h, and 1.7 h, respectively, and remained essentially constant over the dosage range of 10-60 micrograms kg-1 of IV MK-462.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),[ml] / [min],1376,236956,DB00953,Rizatriptan
,8991488,steady-state volume of distribution (Vss),"The values of the plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRT) of MK-462 averaged 1376 mL min-1, 140 L, 1.8 h, and 1.7 h, respectively, and remained essentially constant over the dosage range of 10-60 micrograms kg-1 of IV MK-462.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),l,140,236957,DB00953,Rizatriptan
,8991488,steady-state volume of distribution (Vss),"The values of the plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRT) of MK-462 averaged 1376 mL min-1, 140 L, 1.8 h, and 1.7 h, respectively, and remained essentially constant over the dosage range of 10-60 micrograms kg-1 of IV MK-462.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),h,1.8,236958,DB00953,Rizatriptan
,8991488,plasma terminal half-life (t1/2),"The values of the plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRT) of MK-462 averaged 1376 mL min-1, 140 L, 1.8 h, and 1.7 h, respectively, and remained essentially constant over the dosage range of 10-60 micrograms kg-1 of IV MK-462.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),l,140,236959,DB00953,Rizatriptan
,8991488,plasma terminal half-life (t1/2),"The values of the plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRT) of MK-462 averaged 1376 mL min-1, 140 L, 1.8 h, and 1.7 h, respectively, and remained essentially constant over the dosage range of 10-60 micrograms kg-1 of IV MK-462.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),h,1.8,236960,DB00953,Rizatriptan
,8991488,mean residence time in the body (MRT),"The values of the plasma clearance (CL), steady-state volume of distribution (Vss), plasma terminal half-life (t1/2), and mean residence time in the body (MRT) of MK-462 averaged 1376 mL min-1, 140 L, 1.8 h, and 1.7 h, respectively, and remained essentially constant over the dosage range of 10-60 micrograms kg-1 of IV MK-462.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),h,1.7,236961,DB00953,Rizatriptan
,8991488,apparent CL,"However, as the dose increased from 60 to 90 micrograms kg-1, the mean value of the apparent CL decreased from 1376 to 807 mL min-1.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),[ml] / [min],1376,236962,DB00953,Rizatriptan
,8991488,distribution clearance (CLd),"The following values of two dose-independent parameters were also calculated by using DDA: distribution clearance (CLd) = 2028 mL min-1, and mean transit time in the peripheral tissues (MTTT) = 0.74 h.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),[ml] / [min],2028,236963,DB00953,Rizatriptan
,8991488,mean transit time in the peripheral tissues (MTTT),"The following values of two dose-independent parameters were also calculated by using DDA: distribution clearance (CLd) = 2028 mL min-1, and mean transit time in the peripheral tissues (MTTT) = 0.74 h.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),h,0.74,236964,DB00953,Rizatriptan
,8991488,AUC,"The mean values of AUC, Cmax, tmax, and apparent t1/2 of MK-462 in 12 subjects each receiving a 40 mg tablet of MK-462 without breakfast were 330 ng.h mL-1, 77 ng mL-1, 1.6 h, and 1.8 h, respectively.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),[h·ng] / [ml],330,236965,DB00953,Rizatriptan
,8991488,Cmax,"The mean values of AUC, Cmax, tmax, and apparent t1/2 of MK-462 in 12 subjects each receiving a 40 mg tablet of MK-462 without breakfast were 330 ng.h mL-1, 77 ng mL-1, 1.6 h, and 1.8 h, respectively.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),[ng] / [ml],77,236966,DB00953,Rizatriptan
,8991488,Cmax,"The mean values of AUC, Cmax, tmax, and apparent t1/2 of MK-462 in 12 subjects each receiving a 40 mg tablet of MK-462 without breakfast were 330 ng.h mL-1, 77 ng mL-1, 1.6 h, and 1.8 h, respectively.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),h,1.6,236967,DB00953,Rizatriptan
,8991488,tmax,"The mean values of AUC, Cmax, tmax, and apparent t1/2 of MK-462 in 12 subjects each receiving a 40 mg tablet of MK-462 without breakfast were 330 ng.h mL-1, 77 ng mL-1, 1.6 h, and 1.8 h, respectively.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),[ng] / [ml],77,236968,DB00953,Rizatriptan
,8991488,tmax,"The mean values of AUC, Cmax, tmax, and apparent t1/2 of MK-462 in 12 subjects each receiving a 40 mg tablet of MK-462 without breakfast were 330 ng.h mL-1, 77 ng mL-1, 1.6 h, and 1.8 h, respectively.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),h,1.6,236969,DB00953,Rizatriptan
,8991488,apparent t1/2,"The mean values of AUC, Cmax, tmax, and apparent t1/2 of MK-462 in 12 subjects each receiving a 40 mg tablet of MK-462 without breakfast were 330 ng.h mL-1, 77 ng mL-1, 1.6 h, and 1.8 h, respectively.",Pharmacokinetics and food interaction of MK-462 in healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8991488/),h,1.8,236970,DB00953,Rizatriptan
,34063402,buccal flux,"The optimized film, F1, exhibited significantly higher (p < 0.005) rizatriptan buccal flux (71.94 ± 8.26 µg/cm2/h) with a short lag time.",Development of Mucoadhesive Buccal Film for Rizatriptan: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34063402/),µ,71,250741,DB00953,Rizatriptan
,34063402,AUC0-12h,"The observed AUC0-12h (994.86 ± 95.79 ng.h/mL) in buccal treatment was two-fold higher (p < 0.0001) than the control, and the relative bioavailability judged was 245%.",Development of Mucoadhesive Buccal Film for Rizatriptan: In Vitro and In Vivo Evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34063402/),[h·ng] / [ml],994.86,250742,DB00953,Rizatriptan
,34063402,relative bioavailability,"The observed AUC0-12h (994.86 ± 95.79 ng.h/mL) in buccal treatment was two-fold higher (p < 0.0001) than the control, and the relative bioavailability judged was 245%.",Development of Mucoadhesive Buccal Film for Rizatriptan: In Vitro and In Vivo Evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34063402/),%,245,250743,DB00953,Rizatriptan
,9872339,dose-adjusted,"Relative to the 0.5 mg dose, geometric mean dose-adjusted AUC ratios were 1.04, 1.09, and 1.18 for 1, 2.5, and 5 mg doses, respectively.",Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872339/),,1.04,269609,DB00953,Rizatriptan
,9872339,dose-adjusted,"Relative to the 0.5 mg dose, geometric mean dose-adjusted AUC ratios were 1.04, 1.09, and 1.18 for 1, 2.5, and 5 mg doses, respectively.",Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872339/),,1.09,269610,DB00953,Rizatriptan
,9872339,dose-adjusted,"Relative to the 0.5 mg dose, geometric mean dose-adjusted AUC ratios were 1.04, 1.09, and 1.18 for 1, 2.5, and 5 mg doses, respectively.",Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872339/),,1.18,269611,DB00953,Rizatriptan
,9872339,AUC ratios,"Relative to the 0.5 mg dose, geometric mean dose-adjusted AUC ratios were 1.04, 1.09, and 1.18 for 1, 2.5, and 5 mg doses, respectively.",Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872339/),,1.04,269612,DB00953,Rizatriptan
,9872339,AUC ratios,"Relative to the 0.5 mg dose, geometric mean dose-adjusted AUC ratios were 1.04, 1.09, and 1.18 for 1, 2.5, and 5 mg doses, respectively.",Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872339/),,1.09,269613,DB00953,Rizatriptan
,9872339,AUC ratios,"Relative to the 0.5 mg dose, geometric mean dose-adjusted AUC ratios were 1.04, 1.09, and 1.18 for 1, 2.5, and 5 mg doses, respectively.",Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872339/),,1.18,269614,DB00953,Rizatriptan
,9872339,Apparent plasma clearance (Cl),"Apparent plasma clearance (Cl) ranged between 859 and 941 mL min(-1) from 0.5 to 2.5 mg, but dropped to slightly below 800 mL min(-1) for the 5 mg dose.",Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872339/),[ml] / [min],859 and 941,269615,DB00953,Rizatriptan
below,9872339,Apparent plasma clearance (Cl),"Apparent plasma clearance (Cl) ranged between 859 and 941 mL min(-1) from 0.5 to 2.5 mg, but dropped to slightly below 800 mL min(-1) for the 5 mg dose.",Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872339/),[ml] / [min],800,269616,DB00953,Rizatriptan
,9872339,plasma half-life (t1/2),Mean plasma half-life (t1/2) was 1.5-2.2 h across all doses while mean residence time in the body (MRT) and steady state volume of distribution (Vss) of rizatriptan remained relatively invariant across doses.,Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872339/),h,1.5-2.2,269617,DB00953,Rizatriptan
,9872339,Urinary excretion,Urinary excretion of rizatriptan (Ue) ranged from 14.5 to 34.6% of dose.,Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872339/),%,14.5 to 34.6,269618,DB00953,Rizatriptan
